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Liposome-coated Magnesium Phosphate Nanoparticle for Delivery of Cytochrome C into
Lung Cancer Cells A549

Abstract

by Weizhou Yue
University of the Pacific
2017

Proteins are large biomolecules that have great therapeutic potential in treating
many human diseases. However, chemical/enzymatic degradation, denaturation, and
poor penetration into cells are some of the challenges for clinical use of intracellular
proteins.
Previously, our group has developed cationic lipid-coated magnesium phosphate
nanoparticle (LP MgP NP-CAT) formulations to enhance the intracellular delivery of the
negatively charged protein catalase. The goal of the current research is to develop a
formulation to deliver cytochrome c (CytC), a positively charged protein into lung cancer
cells A549. Specifically, this thesis research prepares and tests liposome-coated
magnesium phosphate nanoparticle for delivery of cytochrome c (CytC LP/MgP).
CytC LP/MgP was designed, prepared and characterized, showing that it had an
average diameter around 150 nm and ζ-potential around +30 mV. The morphology of
CytC LP/MgP was validated by transmission electron microscopy.
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CytC LP/MgP successfully led to the attachment of CytC to A549 cells, as
supported by fluorescence imaging. Intracellular delivery of CytC alleviated the
cytotoxicity of cationic lipids in A549 cells, as suggested by the MTS assay on cell
viability, which could facilitate the clinical use of cationic lipids in drug delivery
systems.
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Chapter 1:
1.1

Current Development of Devices for Intracellular Protein Delivery

Introduction
Proteins represent the most diverse molecules in biology. In the past thirty years,

proteins purified from natural sources or produced from recombinant biotechnology have
found a plethora of applications in modern medicine, including supplementation or
modulation of a biological function, targeting specific cell types, vaccination, and
diagnostics [1]. Up till now, more than a hundred proteins have been approved by FDA
as therapeutic or diagnostic agents in USA. Compared to small molecule drugs, proteins
as therapeutics agents carry the potential advantages of exerting more complicated
activities, higher specificity, higher bio-compatibility and, in average, shorter time for
drug development/approval [1]. With accelerated understanding of the cellular functions
of proteins after the completion of the human genome project, the role of proteins in
modern medicine is expected to expand remarkably in the next decade [1].
Nevertheless, one common challenge of developing protein-based medications is
to achieve an adequate pharmacokinetic profile, including long enough half-life in blood
circulation and sufficient distribution to the target site [2]. After administration, native
proteins are prone to enzymatic degradation and hepatic/renal elimination while
circulating in the blood, and are too large to diffuse into cells. Therefore, the
development of technologies to enhance the delivery of proteins to their target site is
critical for capitalizing on their potential as future therapeutic agents.
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In this chapter, the current development of devices for intracellular protein
delivery is reviewed and summarized.
1.2

Microinjection
Single-cell microinjection has been successfully used to deliver exogenous

proteins, cDNA constructs, peptides, drugs and particles into transfection-challenged
cells through a glass micropipette. Due to its advantage of precise control over dosage
and timing, microinjection has been widely used in studies on primary cultured cells,
transgenic animal production, in vitro fertilization and RNA interference.
The p53 tumor suppressor is a transcription factor frequently mutated in human
malignancies. Tumor-derived p53 missense mutants are defective in sequence-specific
DNA binding and fail to activate p53 target genes, Abarzua et al. showed that
microinjection of mAb PAb421, which was shown previously to restore DNA binding to
selected p53 mutants in vitro, restored the transcription activation function of the resident
mutant p53 in human SW480 colorectal carcinoma cells (arg to his 273, pro to ser 309)
[3]. The results supported the concept of restoring wild-type function to mutant p53 as a
strategy for cancer therapy.
1.3

Electroporation
Electroporation applies an electric current across a cell membrane to perform

temporary “pores” formation, which allow exogenous molecules in the medium to enter
either the cytoplasm or the nucleus, thereby transfecting or transforming the cell.
In vascular smooth muscle cells, rapid tyrosine phosphorylation of phospholipase
C-γ1 (PLC-γ1) is the mechanism of how the binding of angiotensin II occupancy of the
angiotensin II receptor AT1 mobilizes calcium from the cytoplasm to eventually cause the
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contraction of the smooth muscle cell. Marrero et al. reported that intracellular delivery
of pp60c-src antibodies inhibited the angiotensin II phosphorylation of PLC-γ1 in cultured
rat aortic smooth muscle (RASM) cells [4]. These data provided the first evidence for a
direct involvement of pp60c-src kinase in angiotensin II-mediated PLC-γ1
phosphorylation.
1.4

Mesoporous Silica Nanoparticles
Mesoporous silica nanoparticles with high surface areas (>800 m2/g) and tunable

pore diameter (2-10 nm) were synthesized to develop a variety of new delivery
formulations, where different guest molecules, such as small molecular drugs, fluorescent
imaging agents, and proteins, could be absorbed into the mesopores and released into
solutions later.
It is known that cytochrome c (CytC) catalyzes the oxidation of 2,2’-azino-bis(3ethylbenzthiazoline-6-sulfonate) (ABTS) by hydrogen peroxide. Slowing et al. found
that MCM-41-type mesoporous silica nanoparticle (MSN) with a large average pore
diameter (5.4 nm) could serve as a transmembrane delivery vehicle for controlled release
of the protein CytC in live human cervical cancer cells (HeLa), which find many
important pharmaceutical applications as therapeutics and diagnostic agents [5].
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Fig. 1.1. Schematic representation of the MSN transporting cytochrome c through the cell
membrane and releasing the protein into the cytoplasm [5].

1.5

Cell Penetrating Peptides (CPPs)
Short peptides isolated from protein-transduction domains (cell penetrating

peptides or CPPs) of various protein types allow the intracellular delivery of conjugated
(or fused) biomolecules. A wide range of cargos such as antigenic peptides, peptide
nucleic acids, antisense oligonucleotides, full-length proteins, or even nanoparticles and
liposomes have been intracellularly delivered by this way.
Räägel et al. presented the characterization of intracellular trafficking of 3
different CPP–avidin complexes (transportan-, nona-arginine- and Tat-avidin) in Cos-7
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cells related to different endocytic routes during CPP-cargo internalization, which proved
characteristic properties of CPPs chose pathways to gain entry to cells [6].
1.6

Cationic Liposomes
Liposomes are artificial vesicles composed essentially of mostly phospholipids

and have been reported to serve as immunological adjuvants and drugs carriers.
Furthermore, cationic liposomes are currently used as non-viral delivery systems, because
DNA or proteins that are negatively charged readily form a complex with cationic
liposomes via electrostatic interactions.
1.6.1

The Delivery System Composed of TFA-DODAPL and DOPE
Zelphati et al. reported a cationic liposomal formulation composed of a new

trifluoroacetylated lipopolyamine (TFA-DODAPL) and dioleoyl
phosphatidylethanolamine (DOPE), successfully delivered antibodies, dextran sulfates,
phycobiliproteins, albumin, and enzymes (β-galactosidase and proteases) into the
cytoplasm of numerous adherent and suspension cells [7]. This advanced protein
delivery system represented a powerful tool for functional protein delivery and might
have potential for therapeutic applications.
1.6.2

Nanoparticle Composed of DOTAP/DOPE and APOA-I
Amphiphilic residues, such as cell penetrating peptides (CPPs), have been

conjugated to non-lipophilic proteins such as CytC and GFP to anchor the proteins into
the lipid bilayer of nanoparticles (NP). For example, Kim et al. reported that a NP
composed of lipid (DOTAP/DOPE) and apolipoprotein (APOA-I) delivered
intracellularly-acting proteins (e.g. CytC or GFP) into non-small cell lung tumors. This
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nanoparticle holds great potential for the effective delivery of non-lipophilic proteins for
cancer therapy [8].

Fig. 1.2. Schematic representation of nanoparticle preparation for protein delivery [8].

1.6.3

Commercially Available Cationic Lipids
Zuris et al. reported that cationic lipids that are commonly used as nucleic acid

transfection reagents could potently deliver proteins that were fused to negatively
supercharged molecules (e.g. (-30)GFP-Cre, Cas9:sgRNA complexes) [9]. These
findings suggested that the intracellular delivery of polyanionic proteins and
protein:nucleic acid complexes by cationic lipids might expand the research and
therapeutic applications of proteins.
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Fig. 1.3. Strategy for delivering proteins into mammalian cells by fusion or non-covalent
complexation with polyanionic macromolecules and complexation with cationic lipids
[9].

1.6.4

Cationic Liposome Coated-Magnesium Phosphate Nanoparticles (LP/MgP)
The low efficiency of endosomal escape and the high level of lysosomal

degradation are major challenges to all protein delivery systems that enter the cells via
endocytosis. Our group previously developed liposome-coated magnesium phosphate
nanoparticle (LP MgP NP-CAT), which is designed to destabilize the endosome and
release the cargo at lowerd pH, loaded with negatively charged protein that degrades
hydrogen peroxide in cells. Intratracheal administration of LP MgP NP-CAT loaded with
catalase that significantly lowered ROS levels in mouse lungs, demonstrating its great
promise for protein-based therapy in the clinic [10].
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Fig. 1.4. Schematic image representing the LP/MgP for protein delivery [10]. +: Positive
charges of LP/MgP; MgP NP: magnesium phosphate nanoparticles (MgP); red squares:
cargo proteins; and gray circles: lipid membranes (LP) consisting of DOTAP/cholesterol.

1.7

Conclusion
Although the abovementioned delivery devices display their great promises for

therapeutic applications, their drawbacks are also noticeable. Microinjection and
electroporation require specialized equipment and technical skill to prevent cell damage
and is not convenient when a large number of cells need to be assessed simultaneously
for intercellular trafficking; cell penetrating peptides (CPPs) generate too many unwanted
side effects due to their unintended penetration to untargeted normal cells; nanoparticles
including mesoporous silica nanoparticles with large pores and commercially available
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cationic liposomes generally suffer from low tolerance of serum, poor endosomal escape,
and limited in vivo efficacy [9]. Therefore, novel protein delivery systems that could
minimize these drawbacks would lead the advances of protein-based pharmacotherapy.

Table 1.1. Reported intracellular protein delivery systems.
Approaches
Microinjection

vehicles

Cargoes
mAb PAb421

Electroporation
pp60c-src antibodies
Nanoparticles

Mesoporous Silica Nanoparticles with
cytochrome c
large pores

Cell-penetrating Transportan
peptides (CPPs) Oligoarginine
Tat
Liposomes
A trifluoroacetylated lipopolyamine
(TFA-DODAPL) and dioleoyl
phosphatidylethanolamine (DOPE)

Drawbacks
Require specialized equipment and
expertise to prevent cell damage;
inconvenient for delivering to a large
number of cells
Highly disruptive, cytotoxic, and
inefficient
Physicochemical properties limit in
vivo application

avidin

Excessive side effects

antibodies, dextran sulfates,
phycobiliproteins, albumin, and
enzymes (β-galactosidase and
proteases)

Degradation in serum, poor
endosomal escape, limited in vivo
efficacy

A nanoparticle (NP) composed of lipid
intracellular-acting protein drugs
(DOTAP/DOPE) and apolipoprotein
(GFP, cytochrome c)
(APOA-I)

Poor endosomal escape

negatively supercharged proteins
Commercially available cationic lipids ((−30)GFP-Cre, Cas9:sgRNA
complexes)

Degradation in serum, poor
endosomal escape, limited in vivo
efficacy
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Chapter 2:

Design of Magnesium Phosphate Nanoparticles with Cationic Lipid

Coating for Intracellular Delivery of Cytochrome C (CytC LP/MgP)
2.1

Introduction
Current non-viral vectors possess several potential advantages, such as ease of

large-scale production, the capacity to carry large cargos as well as the potential to
exhibit relatively lower immunogenicity in comparison to viral approaches. However,
non-viral vectors typically exhibit relatively lower delivery efficiencies when compared
to viral approaches. For non-viral vectors, lower delivery efficiencies (in comparison to
viral approaches) were observed because of entrapment in endosome/lysosome,
degradation, and inefficient cellular uptake. To solve these problems, Olton et al.
developed a formulation of CaP nanoparticles with cationic lipid-coating because of
CaP’s biodegradability, biocompatibility, and ease of handling. CaP increased the
fraction of the cargo that both successfully escaped from endosomes and effectively
trafficked to the cytosol. The cationic lipid-coating of the formulation also helped to
protect the cargo from denaturation [11].
Inspired by this design, our group recently developed a novel delivery systemmagnesium phosphate nanoparticle coated with cationic lipid (LP/MgP) for intracellular
protein delivery. Protein cargos were chosen because protein therapeutics have high
specificity in action, and innate proteins for therapy are well tolerated and less likely to
elicit immune responses. Therapeutic protein cargos also enjoy faster clinical
development and shorter FDA approval time than small-molecule drugs. Moreover,
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protein therapeutics are easier to obtain extensive patent protection. Negatively charged
protein catalase was complexed with cationic liposome-coated magnesium phosphate
nanoparticles by electrostatic interaction. The formulation reduced ROS level by 60% in
EA.hy926 cells [10].
Based on the foregoing, the hypothesis of this thesis project is that liposomecoated magnesium phosphate nanoparticles (LP/MgP) can also enhance the intracellular
delivery of positively charged proteins such as cytochrome c (CytC). CytC can be
complexed non-specifically and delivered by rehydrated lipids in vitro, where this
protein-liposome complexation is dependent on high protein concentrations.
This thesis research proposes to formulate liposome-coated magnesium phosphate
nanoparticles containing the positively charged cargo protein, cytochrome c (CytC
LP/MgP). Such CytC LP/MgP formulation comprises a core of MgP, a coating of
cationic lipids, and the encapsulated cargo protein cytochrome c.

Fig. 2.1. Diagram of CytC LP/MgP.
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2.1.1

Lipid – DOTAP
Kawakami et al. demonstrated that cationic liposomes composed of

DOTAP/cholesterol accumulated in the lung one minute after intravenous injection [12].
Cationic liposomes are internalized by endocytosis in these cells. Notably, fusion of
liposomes with the endosomal membrane during endosome maturation can facilitate the
endosomal escape of cationic lipid-delivered cargo [13]. Furthermore, C18 unsaturated
hydrophobic chains of cationic lipid DOTAP allow DOTAP/cholesterol liposomes to be
extruded through the 100-nm polycarbonate membrane readily at room temperature. Last
but not least, cationic lipids are often mixed with so-called helper lipids, such as dioleoyl
phosphatidylethanolamine (DOPE) or cholesterol. The helper lipids would enhance the
lipid transition from the lamellar phase to a non-lamellar structure, which would improve
the delivery efficiency [14].
However, high cytotoxicity was observed in a concentration-dependent manner
for DOTAP/cholesterol liposomes. It is well-known that the cytotoxicity of cationic
liposomes is due to apoptosis. Mechanisms of toxicity by cationic liposomes include
change of mitochondrial membrane potential, generation of reactive oxygen species
(ROS), dissociation of cytochrome c from the inner mitochondrial membrane, formation
of the mitochondrial outer membrane permeabilization pore (MOMPP), release of
cytochrome c, and apoptosis [15]. Therefore, alleviating the toxicity of cationic
liposomes becomes an important issue for the development of liposomal delivery
systems.
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Fig. 2.2. Chemical structure of DOTAP, a commonly used cationic lipid [15].

2.1.2

Magnesium Phosphate Nanoparticle (MgP) as the Core of the Proposed

Formulation
Calcium phosphate precipitation has been one of the most common techniques to
transfect cultured cells in biological research. Roy et al. reported that after calcium
chloride and sodium phosphate solutions were each dispersed into organic solvents to
form two separate water-in-oil microemulsions, calcium phosphate precipitates at 100120 nm in diameter were reliably generated by mixing two emulsions at low temperature
[16]. Later, Li et al. reported that when calcium phosphate precipitates were coated with
sodium citrate, excessive negative surface charges prevented their aggregation.
Moreover, when such negatively charged calcium phosphate precipitates were mixed
with cationic liposomes consisting of DOTAP/cholesterol, the cationic liposomes
spontaneously wrapped around the calcium phosphate precipitates by electrostatic
interaction to form calcium phosphate nano-precipitates that are coated by concentric
lipid membranes [17].
One remarkable property of these nano-precipitates is that they promptly dissolve
when the pH decreases from 8 to 5. Therefore, calcium phosphate precipitates are
expected to dissolve and turn into a highly concentrated calcium phosphate solution after
their endocytosis, when they are exposed to the acidic endosomal pH. The solution
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would then absorb water because of its high osmotic pressure, swell to destabilize the
endosome membrane, and release the cargo into the cytosol, thus greatly enhancing the
delivery efficiency.

Fig. 2.3. The hypothesized release process of cargos that are entrapped in liposomecoated calcium phosphate nano-precipitates in endosomes [17].
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Under physiological conditions, the extracellular Ca2+ concentration is ~1.2 mM
whereas the cytosolic concentration is ~0.1 μM. Low to moderate elevation of the Ca2+
concentration (0.2~0.4 μM) in the cytosol triggers apoptosis and higher cytosolic
concentrations of Ca2+ (>1 μM) are associated with necrosis [18]. Therefore, it is
beneficial to use magnesium phosphate precipitates (MgP) as the core of the proposed
formulation instead of calcium phosphate to achieve lower cytotoxicity.
2.1.3

Cargo Protein Cytochrome C (CytC)
Cytochrome c (CytC) is a small hemeprotein found loosely associated with the

inner membrane of mitochondria, and is a member of the family of cytochromes. Unlike
other cytochromes, CytC is highly water-soluble. It is an essential component of the
electron transport chain (ETC) with isoelectric point (pI) values in the range of 10.0-10.5,
therefore carrying excessive positive charges at pH 7.4.
Interestingly, it has long been known that isolated mitochondria can reversibly
release and take up CytC, while the latter restores mitochondrial function [19]. Piel et al.
reported an interesting and medically important example for the reversibility of CytC
release, where intravenously injected CytC was taken into the cardiomyocytes and
significantly improved the mitochondrial function in an animal model of sepsis. The
survival rate increased from 15% for the controls to about 50% in the septic mice that
received the CytC injections [20], [21].
CytC is also known as a mediator of apoptosis through the intrinsic apoptosis
pathway. CytC is released from mitochondria into the cytosol due to formation of
mitochondrial outer membrane permeabilization pore (MOMPP) when cells are stressed,
and binds with apoptotic protease-activating factor 1 (Apaf-1). The binding in turn
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induced the binding between the CytC/Apaf-1 complex and dATP, which is necessary for
oligomerization and formation of the apoptosome. The apoptosome then recruits
multiple procaspase-9 molecules and promotes their cleavage and activation into what are
known as initiators of apoptosis. Caspase-9 bound to the apoptosome acts as the
cleavage factor of caspase-3, which is considered as the major enzyme that initiates the
degradation of numerous cellular proteins to complete the apoptosis process [22].
Although CytC release is an essential step in the apoptotic cascade but that CytC
release is not sufficient to induce death in all cells. CytC-induced apoptosis is dependent
on the concentration of cytosolic CytC, in that the release of endogenous CytC occurs
proportionally to the extent of cellular ‘stress’ and that a certain threshold of released
CytC must be reached before a cell commits to apoptosis [23].

34

Fig. 2.4. Apoptosis pathways that involve cytochrome c (CytC) [22].

Free CytC also functions as a radical scavenger within the inner-membrane space.
The oxidized form of CytC neutralizes superoxide, while both reduced and oxidized
states of CytC deactivate hydrogen peroxide. Since CytC constantly undergoes
oxidation/reduction cycles in a respiring cell, both detoxification reactions can take place
in the mitochondria by cytochrome c as a strong antioxidant [22].
2.2

Proposed Mechanism of Protein Delivery by the Proposed CytC LP/MgP
At pH 7.4, the delivery system is expected to protect the cargo protein and to

interact with the target cells either by ionic interactions. After endocytosis, the elevated
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concentration of protons inside the endosome will dissolve the MgP nano-core, which
will then absorb water, expand in volume, and destabilize the endosomal membrane to
release the cargo protein into cytosol.
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Chapter 3:

Preparation and Physiochemical Characterization of Magnesium

Phosphate Nanoparticles with Cationic Lipid coating for Intracellular Delivery of
Cytochrome C (CytC LP/MgP)
3.1

Materials
Magnesium chloride (Acros Organics), trisodium phosphate (Mallinckrodt

Chemical), cyclohexane (EMD Millipore), Triton-X100 (EMD Millipore), 1-hexanol
(Alfa Aesar), sodium citrate (J. T. Baker Chemical), absolute ethanol (Fisher Scientific),
sulfuric acid (Acros), hydrogen peroxide 35% (Sigma-Aldrich), silica gel (Alfa Aesar),
ammonium molybdate tetrahydrate (Sigma-Aldrich), Ascorbic acid (Acros Organics),
phosphorous standard (Ricca Chemical), cytochrome c (MP Biomedicals), 1,2-dioleoyl3-trimethylammonium-propane (DOTAP) (Avanti Polar Lipids), cholesterol (SigmaAldrich), and HEPES (Fisher Scientific) were used as purchased without further
purification.
3.2

Methods

3.2.1

Preparation and Characterization of Cytochrome C-encapsulated Cationic

Liposomes (CytC LP)
Preparation of cytochrome c-encapsulated liposomes. Cytochrome c powder
with different weight was dissolved in 1 ml pH 7.4, 5 mM HEPES buffer to obtain
cytochrome c solution with different concentration. Aliquots of 156.48 µL 35.79 mM
DOTAP and 74.24 µL 32.33 mM cholesterol solutions in chloroform, which were in the
7:3 molar ratio to yield a mixture of 8 µmol total lipids, were added into a Pyrex glass
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tube, and then evaporated by a rotary evaporator at room temperature for 15 minutes to
form a lipid film. The lipid film was placed under high vacuum for at least 4 hours to
remove the residual solvent. The dried lipid film was hydrated with 0.7 mL cytochrome
c solution and mildly vortexed for 20 seconds at room temperature to obtain a suspension
of cytochrome c-encapsulated liposomes. The suspension was extruded 13 times through
100 nm polycarbonate membrane (Nucleopore, Pleasanton, CA) by a Mini-Extruder
(Avanti Polar Lipids, Alabaster, AL) at room temperature to yield cytochrome cencapsulated liposomes of smaller and more homogenous size.

Fig. 3.1. Preparation of cytochrome c-encapsulated cationic liposomes.

Size and ζ-potential measurements of cytochrome c-encapsulated liposomes.
A 50-μL suspension of cytochrome c-encapsulated liposomes (CytC LP) was carefully
added into a 10-mm square polystyrene cuvette (SARSTEDT, Germany) without creating
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any air bubble. The cuvette was closed with a lid, slightly agitated and placed into a
Malvern Zetasizer for size measurements. The temperature was maintained at 25 ℃.
After size measurements, the suspension in the cuvette was diluted into 1 mL pH
7.4, 5 mM HEPES buffer and the ζ-potential was measured immediately. The diluted
suspension was slowly infused into a folded capillary cell (Malvern Instruments, UK)
without creating any air bubble. The volume of the diluted suspension was adequate to
completely cover the electrodes of the cell. The two openings of the cell were closed
with two lids and the cell was placed into the Malvern Zetasizer. The sample was
equilibrated to 25 ℃ before measurements.
All the samples were measured in triplicates and the data were reported as mean ±
standard deviation of the triplicate measurements.
TEM imaging. The TEM was performed at the Electron Imaging Facility,
Department of Molecular and Cellular Biology, UC Davis with the help from Dr. Fei
Guo. Briefly, a 5-µL the suspension of cytochrome c-encapsulated liposomes (CytC LP)
was dropped onto a Pure Carbon Film Copper TEM grid on 400 mesh (TED PELLA
INC., Redding, California). The suspension on the gird was air-dried for about 1 minute
and the excess fluid was blotted away with filter paper. A few drops of uranyl acetate
were then applied to the grid to generate a thin film of the suspension on the TEM grid,
which was then immediately transferred onto a JEOL-1230 microscope for imaging at an
accelerating voltage of 100 kV. The digital images were recorded and analyzed with
EMMENU4 (TIETZ imaging software).
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3.2.2

Preparation and Characterization of Magnesium Phosphate Nanoparticles

(MgP)
Preparation of MgP nanoparticles. Magnesium phosphate nanoparticle (MgP)
was prepared by micro-emulsion precipitation. A 15-mL mixture of organic solvents
consisting of 75% cyclohexane, 15% Triton-X100 and 10% hexanol was added each into
two round bottom flasks and stirred for 15 minutes. An aliquot (300 µl) of 333.33 mM
MgCl2 aqueous solution was added into one flask and another 300 µl 500 mM Na3PO4
aqueous solution into the other flask. The two mixtures were each stirred continuously for
30 minutes to form reverse water-in-oil (w/o) microemulsions. The Na3PO4
microemulsion was promptly added into the MgCl2 microemulsion followed by another
30 minutes of continuous stirring to generate MgP nanoparticles. Sodium citrate (250
µL, 15 mM aqueous solution) was then added dropwise into the microemulsion to endow
the MgP nanoparticles with negative surface charges. The mixture was then stirred for
another 15 minutes until the microemulsion turned translucent.
For the separation of the MgP nanoparticles, 4 g silica gel (60-200 mesh) was
suspended in 30 mL ethanol. The afore prepared microemulsion containing the MgP
nanoparticle was poured into the silica gel-ethanol mixture with continuous stirring for 15
minutes to break the microemulsion and to adsorb the magnesium phosphate (MgP)
nanoparticles onto the silica gel. Organic solvents were washed away with 200 mL
ethanol and magnesium phosphate nanoparticles were then sequentially eluted with 15
mL 75% ethanol, 15 mL 50% ethanol, and two 15 mL 25% ethanol in water. The eluted
nanoparticles were collected in eight 7.5 mL fractions. Suspensions of MgP
nanoparticles in water were obtained after removing ethanol by rotary evaporation. The
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entire process was carried out at 4ºC temperature, and the MgP nanoparticles were
quantified using the phosphorous assay as detailed in the following section.

Fig. 3.2. Preparation of MgP nanoparticles.
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Phosphorus assay. 10 N H2SO4 was prepared by carefully adding 1 mL stock 35
N H2SO4 to 2.5 mL deionized water. 10% H2O2 was prepared by mixing 1 mL stock
35% H2O2 with 2.5 mL deionized water. Molybdate reagent was prepared by dissolving
0.22 g ammonium molybdate tetrahydrate in 2.5 mL of 10 N H2SO4, followed by dilution
with deionized water to 100 mL. 10% ascorbic acid solution was obtained by dissolving
5 g ascorbic acid in 50 g deionized water.
For the preparation of standards, 6 different volumes of a phosphorus standard
solution were placed into 6 different clean Pyrex tubes as follows: 0 nmol (0 µL) as
blank, 125 nmol (77.5 µL), 250 nmol (155 µL), 375 nmol (232.5 µL), 500 nmol (310
µL), and 625 nmol (387.5 µL).
For each sample, 20 µL of a suspension of MgP nanoparticle was placed into the
bottom of a Pyrex tube. An aliquot (0.4 mL) of 10 N H2SO4 was added to each sample
and standard. All tubes were then heated in a solid anodized aluminum block in the fume
hood at 200-210 ℃ for 60 minutes. The tubes were removed from the block and allowed
to cool for 10 minutes at room temperature. An aliquot (0.1 mL) of 10% H2O2 was added
to each tube. All tubes were heated again at 190-210 ℃ for 10 minutes and then cooled
at room temperature for 10 minutes. The molybdate reagent (4.7 mL) and 10% ascorbic
acid (0.5 ml) were added to each tube and all tubes were vortexed immediately for 10
seconds. All tubes were then heated at 100 ℃ for 10 minutes, when blue color was
observed in tubes containing substantial phosphate. The tubes were then cooled on the ice
to reach room temperature rapidly. The UV absorbance at 800 nm was then determined
by UV-visible spectrophotometer, UV-1601 (Shimadzu, Japan) after the standard tube
containing 0 nmol phosphate used to manually adjust the absorbance to zero. A
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calibration curve was generated using the absorbance of standard samples and used to
determine the amount of phosphorus in unknown samples.
Size and ζ-potential measurements of MgP nanoparticles. An aliquot (50 μL)
of a suspension of MgP nanoparticles was carefully added into a 10-mm square
polystyrene cuvette (SARSTEDT, Germany) without creating any air bubble. The
cuvette was closed with a lid, slightly agitated and placed into the Malvern Zetasizer.
The temperature was maintained at 25 ℃.
After size measurements, the suspension in the cuvette was diluted to 1 mL using
deionized water and the ζ-potential was measured immediately. The diluted suspension
was slowly infused into a folded capillary cell (Malvern Instruments, UK) without
creating any air bubble. The volume of the diluted suspension was adequate to
completely cover the electrodes of the cell. The two openings of the cell were closed
with two lids and was placed into the Zetasizer. The sample was equilibrated to 25 ℃
before measurements.
All the measurements were in triplicate and the data were reported as mean ±
standard deviation of the triplicates.
TEM imaging. The TEM was performed at the Electron Imaging Facility,
Department of Molecular and Cellular Biology, UC Davis with the help from Dr. Fei
Guo. Briefly, a 5-µL the suspension of magnesium phosphate nanoparticles (MgP) was
dropped onto a Pure Carbon Film Copper TEM grid on 400 mesh (TED PELLA INC.,
Redding, California). The suspension on the gird was air-dried for about 1 minute and
the excess fluid was blotted away with filter paper. The thin film of the suspension on
the TEM grid was then immediately transferred onto a JEOL-1230 microscope for
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imaging at an accelerating voltage of 100 kV. The digital images were recorded and
analyzed with EMMENU4 (TIETZ imaging software).
3.2.3

Wrapping of Magnesium Phosphate Nanoparticles with Cytochrome C-

encapsulated Cationic Liposomes (CytC LP/MgP)
Preparation of MgP nanoparticles coated with cytochrome c-encapsulated
liposomes. The phosphoric concentration of MgP nanoparticles was determined by the
previous phosphorus assay so that the amount of MgP nanoparticles to be mixed with
CytC LP matched a 7:3 molar ratio between the amount of total lipids in CytC LP and the
amount of phosphorus in MgP nanoparticles. The amount of MgP nanoparticles to be
added to the CytC LP was determined based on the phosphorus assay, and the
corresponding volume of the suspension of MgP nannoparticles was mixed with CytC LP
for 1 hour at room temperature. Appropriate volume of pH 7.4, 5 mM HEPES buffer was
used to dilute CytC solution to reach an appropriate concentration.
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Fig. 3.3. Spontaneous wrapping of negatively charged MgP nanoparticles by cationic
liposomes.

Size and ζ-potential measurements of cytochrome c-encapsulated liposomes
with MgP nanoparticles. An aliquot (50 μL) of a suspension of cytochrome cencapsulated liposomes with MgP nanoparticles (CytC LP/MgP) was carefully added into
a 10-mm square polystyrene cuvette (SARSTEDT, Germany) without creating any air
bubble. The cuvette was closed with a lid, slightly agitated and placed into the Malvern
Zetasizer. The temperature was maintained at 25 ℃.
After size measurements, the suspension in the cuvette was diluted to 1 mL using
deionized water and the ζ-potential was measured immediately. The diluted suspension
was slowly infused into a folded capillary cell (Malvern Instruments, UK) without
creating any air bubble. The volume of the diluted suspension was adequate to
completely cover the electrodes of the cell. The two openings of the cell were closed
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with two lids and was placed into the Zetasizer. The sample was equilibrated to 25 ℃
before measurements.
All the measurements were in triplicate and the data were reported as mean ±
standard deviation of the triplicates.
TEM imaging. The TEM was performed at the Electron Imaging Facility,
Department of Molecular and Cellular Biology, UC Davis with the help from Dr. Fei
Guo. Briefly, a 5-µL the suspension of cytochrome c-encapsulated liposomes with MgP
nanoparticles (CytC LP/MgP) was dropped onto a Pure Carbon Film Copper TEM grid
on 400 mesh (TED PELLA INC., Redding, California). The suspension on the gird was
air-dried for about 1 minute and the excess fluid was blotted away with filter paper. A
few drops of uranyl acetate were then applied to the grid to generate a thin film of the
suspension on the TEM grid, which was then immediately transferred onto a JEOL-1230
microscope for imaging at an accelerating voltage of 100 kV. The digital images were
recorded and analyzed with EMMENU4 (TIETZ imaging software).
3.3

Results

3.3.1

Phosphorus Assay
The phosphate in the proposed formulation is important for buffering the protons,

and thus for preventing the acid-induced protein denaturation. The phosphate also
contributes to the high osmotic pressure from the dissolved MgP. The MgP nanoparticles
are quantified using the phosphorus assay. The concentration of phosphate ions in a
fraction of nanoparticle is quantified based on a colorimetric method.
In the gradient elution of MgP nanoparticles, the concentration of phosphates in
the eluant fractions depended on the percentage of water in the eluting solvent. The

46
result (Fig. 3.4.) shows that the concentration of phosphates in the second fraction that
was eluted with 25% ethanol in water was the highest at 24.53±3.22 nmol/mL. It is
advisable to perform this assay every time in order to quantify phosphates present in the
sample.

Fig. 3.4. Concentration of phosphate in fractions eluted with 25% of ethanol collected
from chromatograph.

The eluted MgP nanoparticles were collected in eight 7.5 mL fractions. Two
fractions each were collected after elution with 75% and 50% ethanol. Four fractions
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were collected after elution with 25% ethanol. Majority of phosphate concentrated in the
second fraction of the eluent generated with 25% ethanol.
The initial preparation of MgP nanoparticles used 500 mM MgCl2 and 500 mM
(NH4)2HPO4 aqueous solutions. The resultant mixed precipitates of dibasic magnesium
phosphate trihydrate (newberyite, MgHPO4∙3(H2O)) and cattiite (Mg3(PO4)2∙22H2O) at
pH 7.4, 4 ℃ [24], and a Mg2+:PO43- ratio of 1:1 showed relatively low phosphorous
concentration of 7.79±0.93 nmol/mL in the second fraction that was eluted with 25%
ethanol (Fig. 3.5.).
Alternatively, 333.33 mM MgCl2 and 500 mM Na2HPO4 aqueous solutions were
mixed in a physiological molar ratio of Mg2+:PO43- = 2:3. Although the same mixed
precipitates were produced [24], the resultant MgP nanoparticles showed a relatively high
phosphate concentration of 19.88±2.93 nmol/mL in the second fraction that was eluted
with 25% ethanol (Fig. 3.5.).
As another alternative, 333.33 mM MgCl2 and 500 mM Na3PO4 aqueous
solutions were mixed in a physiological molar ratio of Mg2+:PO43- of 2:3, which only
formed cattiite (Mg3(PO4)2∙22H2O) precipitates at pH 7.4, 4 ℃ [24]. Surprisingly, the
resultant MgP nanoparticles showed a phosphate concentration of 24.53±3.22 nmol/mL
in the second fraction that was eluted with 25% ethanol (Fig. 3.5.), which is a much
higher phosphate concentration than the previous two conditions of making MgP
nanoparticles.
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Fig. 3.5. Na3PO4 improved the phosphorous concentration in magnesium phosphate
nanoparticles (MgP).

3.3.2

Colloidal Properties of MgP, CytC LP and CytC LP/MgP
The result of size and surface charge measured by dynamic light scattering (DLS)

(Table 3.1.) shows that the average diameter of both CytC LP and CytC LP/MgP were
around 150 nm. Surprisingly, the size distribution by volume of MgP showed two peaks,
which will be discussed later. The ζ-potential changed with compositions of the colloid,
from -9.58 mV of negatively charged MgP, to 48.1 mV of CytC LP due to the cationic
lipids, and then to 27.2 mV of the final formulation of CytC LP/MgP that was made of
both MgP and CytC LP.
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Table 3.1. Size and ζ -potential of MgP, CytC LP and CytC LP/MgP.

Size (nm)

PDI

ζ-Potential (mV)

CytC LP

124.6±38.70

0.058

48.1±9.80

MgP

61.08±9.915
380.7±96.47
(two peaks)

0.362

-9.58±4.13

CytC LP/MgP

158.0±64.17

0.099

27.2±7.30

Each value represents the mean±S.D. of at least three experiments.

3.3.3

TEM Imaging of MgP, CytC LP and CytC LP/MgP
Fig. 3.6. (A) shows that most MgP nanoparticles in TEM images matched the first

peak in the size distribution of MgP as measured by DLS. This phenomenon will be
discussed later. The other finding is that although the electrostatic repulsion brought by
sodium citrate kept nanoparticles separated, some MgP still stuck together.
Fig. 3.6. (B) shows that the cargo protein cytochrome c was encapsulated into
CytC LP.
Fig. 3.6. (C) is the TEM image of CytC LP/MgP. MgP nanoparticles were in the
center of liposomes as expected.
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B
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C
(with negative staining)

(without negative staining)

Fig. 3.6. TEM images of (A) MgP, (B) CytC LP, and (C) CytC LP/MgP.

3.4

Discussion

3.4.1

MgP Produced by the Strategy of Microfluidic Mixing
The NanoAssemblr Benchtop (Precision Nanosystems, Vancouver, BC) is a

nanoparticle synthesis system, whose proprietary microfluidics technology enables
controlled, bottom-up, molecular self-assembly of nanoparticles through millisecond
mixing of components at nanoliter scale. This technique is time-saving and allows largescale preparation of MgP nanoparticles within one day. However, the best result (Fig.
3.6.) of MgP preparation with a size of 79.61±25.82 nm in diameter and a ζ-potential of 8.00±7.28 mV was not reproducible. Consequently, the micro-emulsion method was
eventually elected over this alternative method.
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Fig. 3.7. The most optimized size of MgP generated by the NanoAssemblr Benchtop.

3.4.2

Comparison of DLS and TEM Characterizations of CytC LP/MgP
Dynamic light scattering (DLS) measures the size and surface zeta potential of

small particles. Brownian motion of water molecules moves small, suspended particles
in and out of the detection of their scattered light to cause fluctuation of the scattered
light intensity. The fluctuation can then be used to calculate the hydrodynamic diameter
of the particles. DLS is convenient and can detect a large population of the particles in
the suspension. However, DLS cannot measure the size of the particle core, the size of
varied surface structures, and is limited by the particle concentration.
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Transmission electron microscope (TEM) can be used to examine details of the
structure of a formulation, such as aggregations and cores with a simple sample
preparation. TEM is not easily accessible in common labs and quantitation of the size of
particles need to sample an enormous number of images, which is time-consuming and
inconvenient.
As shown in Fig. 3.8., two peaks were observed in the DLS analysis of the size of
MgP nanoparticles. The first peak showed the hydrodynamic diameter of 61.08±9.915
nm, which possessed 56.2% by volume, indicating this is the diameter that reflect the size
of most of the MgP nanoparticles. The second peak showed the size of 380.7±96.47 nm,
which possessed 43.8% by volume, suggesting that MgP might undergo aggregation.
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Fig. 3.8. Size distribution by volume of MgP measured by DLS.

As shown in Fig. 3.6. (A), the aggregation of MgP nanoparticles were directly
observed by TEM. Despite the addition of sodium citrate, the ζ-potential of MgP was
only slightly negative around -10 mV whereas a surface charge of either higher than +30
mV or lower than -30 mV is needed keep the particles stable in a suspension. Because of
this, the particles of MgP could not sufficiently repulse one another by electrostatic force
to prevent aggregation.
DLS studies showed two peaks of 380.7±96.47 nm and 61.08±9.915 nm in
hydrodynamic diameter for MgP, one peak of 124.6±38.70 nm for CytC LP, and one
peak of 158.0±64.17 nm for the final formulation of CytC LP/MgP. From TEM image
(Fig. 3.6. (C)), the size of the final formulation of CytC LP/MgP was around 100 nm,

55
which was still in the range of size distribution by volume of DLS. There were two
possible reasons to explain why the size of final CytC LP/MgP (Fig. 3.9.) was not close
to the predominant size of MgP around 61.08 nm: 1) from Fig. 3.6. (C), liposomes
engulfed more than one MgP nanoparticles in the core to give to a larger size of final
CytC LP/MgP; 2) lipid membranes loosely wrapped around the MgP nano-core, to form a
relatively thick liposomal shell. Further TEM investigation is needed to confirm these
speculations.
From TEM image (Fig. 3.6. (C)), CytC LP/MgP carrying a magnesium phosphate
nano-core, a coating of lipid membranes encapsulated with cargo protein CytC was
successfully prepared. There was a mechanism how the interaction happened between
inorganic nanoparticles and lipid membranes: engulfment of negatively charged MgP
with cationic CytC LP, which can be reflected on the change of ζ-potential. When the
engulfment happened, the -potential changed from 48.1 mV on CytC LP to 27.2 mV on
the final formulation of CytC LP/MgP, which can be explained by the disproportional
distribution of positive charges to the inside of CytC LP/MgP due to the electrostatic
interaction between a large amount of positive charges on lipid membranes and
negatively charged MgP, leading to the decrement of the density of positive charges
outside of CytC LP/MgP.
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Fig. 3.9. Volume distribution of the size of CytC LP/MgP per DLS.

3.5

Conclusion
CytC LP/MgP was successfully prepared and its physicochemical properties were

characterized. CytC LP/MgP had the approximate size of 150 nm in diameter and the
surface charge around 30 mV.
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Chapter 4:

Characterization of Cationic Liposome-coated Magnesium Phosphate

Nanoparticles for Intracellular Delivery of Cytochrome C (CytC LP/MgP) into
Lung Cancer Cells A549
4.1

Introduction
A549, a lung adenocarcinoma cell line belongs to non-small cell lung cancer

(NSCLC), which accounts for 40% of all lung cancers. Adenocarcinoma occurs mainly
in current and former smokers, but is also the most common type of lung cancer seen in
non-smokers. Adenocarcinoma is more common in women than in men and is more
likely to occur in young people than other types of lung cancer [25]. Cytochrome c
(CytC) is a potential anticancer protein that may induce apoptosis by the mitochondrial
pathway. Cellular uptake of CytC in different formulations was monitored by greenfluorescent dye Alexa Fluor® 488 that can be conjugated to the protein. The MTS Assay
on cell viability was conducted to study the cell killing effect of CytC LP/MgP in A549
cells.
4.2

Materials
A549 cells were purchased from ATCC, cytochrome c (MP Biomedicals),

DMEM/F-12, 50/50, 1X (Corning), fetal bovine serum (Gemini), penicillin-streptomycin
solution (Cellgro), L-glutamine(Cellgro), trypsin 0.25% (1X) (HyClone), Alexa FluorTM
488 carboxylic acid, succinimidyl ester (Thermo Fisher Scientific), DMSO (Fisher
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Scientific), PBS with 1 M NaCl solution (Santa Cruz Biotechnology), MitoRed
(PromoKine), PBS, 1X (Corning), 4% paraformaldehyde in phosphate-buffered saline
(Boston BioProducts), Hoechst 33342 (Thermo Scientific), RPMI medium 1640 (1X)
(Gibco), CellTiter96® AQueous One solution cell proliferation assay (Promega) were
purchased and used without further purification.
4.3

Methods

4.3.1

Fluorescence Imaging Analysis
The preparations of formulations. Conjugation of Alexa Fluor® 488 to

cytochrome c (Alexa 488-labeled CytC). 10 mg of cytochrome c was dissolved in 1 mL
of pH 8.3, 5 mM HEPES buffer. Alexa Fluor™ 488 NHS Ester (Succinimidyl Ester) was
dissolved in DMSO at 10 mg/mL. While stirring or vortexing the cytochrome c solution,
75 μL of the reactive dye solution was slowly added. The reaction mixture was incubated
for 1 hour at room temperature with continuous stirring. The conjugate was separated
from unreacted labeling reagent using Amicon® Ultra 15 mL centrifugal filter (EMD
Millipore, Billerica, MA) with 3 kDa molecular weight cutoff according to the following.
The mixture of cytochrome c and dye was diluted to 4 mL with pH 7.4, 5 mM HEPES
buffer. The diluted mixture was centrifuged at 4000 x g at 25 °C for 1 hour. The
concentrate in the filter device sample reservoir was diluted to 4 mL again and then
centrifuged for another 1 hour. The concentrate was diluted back to 2 mL to yield 245.14
µM Alexa Fluor® 488-labeled cytochrome c (Alexa 488-labeled CytC) solution. HEPES
buffer (0.2 mL, 5 mM at pH 7.4) was added to dilute the resultant suspension of Alexa
488-labeled CytC to 146.95 µM.
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Preparation of LP/MgP containing Alexa Fluor® 488-labeled cytochrome c
(Alexa 488-labeled CytC LP/MgP). DOTAP (156.48 µL 35.79 mM) and cholesterol
(74.24 µL 32.33 mM) solutions in chloroform were added into a Pyrex glass tube to yield
a mixture of 8 µmol total lipids in 7:3 molar ratio. The organic solvent of the mixture was
evaporated by a rotary evaporator at room temperature for 15 minutes to form a lipid
film, which was placed under high vacuum condition for at least 4 hours to remove the
residual solvent. The dried lipid film was hydrated with 0.7 mL of 245.14 µM Alexa
Fluor® 488-labeled cytochrome c solution and mildly vortexed for 20 seconds at room
temperature to obtain a suspension of liposomes containing Alexa Fluor® 488-labeled
cytochrome c (Alexa 488-labeled CytC LP). The suspension was extruded 13 time
through 100 nm polycarbonate membrane (Nucleopore, Pleasanton, CA) by a MiniExtruder (Avanti Polar Lipids, Alabaster, AL) at room temperature. Based on the
phosphorus assay, 138.46 µL of MgP nanoparticles, which carried the phosphoric
concentration of 10.61 mM, was mixed with 0.3 mL of Alexa 488-labeled CytC LP,
followed by incubation for 1 hour at room temperature. Size and ζ-potential of Alexa
488-labeled CytC LP with MgP nanoparticles (Alexa 488-labeled CytC LP/MgP) were
measured by the Zetasizer, when 61.54 µL of pH 7.4, 5 mM HEPES buffer was added to
obtain 146.95 µM Alexa Fluor® 488-labeled CytC, 6.85 mM total lipids, and 2.94 mM
phosphate from MgP in the final formulation.
Preparation of Alexa Fluor® 488-labeled cytochrome c-complexed with MgP
nanoparticles (Alexa 488-labeled CytC+MgP). Based on the phosphorus assay, 138.46
µL of MgP nanoparticles, which carry the phosphoric concentration was 10.61 mM, was
mixed with 0.3 mL of Alexa 488-labeled CytC, followed by incubation for 1 hour at
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room temperature. Size and ζ-potential of Alexa Fluor® 488-labeled cytochrome ccomplexed with MgP nanoparticles (Alexa 488-labeled CytC+MgP) were measured by
the Zetasizer, for which 61.54 µL of pH 7.4, 5 mM HEPES buffer was added to obtain
146.95 µM Alexa Fluor® 488-labeled CytC and 2.94 mM phosphate from MgP in the
final formulation.
Preparation of bare cationic liposomes (bare LP). DOTAP (156.48 µL 35.79
mM) and cholesterol (74.24 µL 32.33 mM) solutions in chloroform were added into a
Pyrex glass tube to yield a mixture of 8 µmol total lipids in 7:3 molar ratio. The organic
solvent of the mixture was evaporated by a rotary evaporator at room temperature for 15
minutes to form a lipid film, which was placed under high vacuum condition for at least 4
hours to remove the residual solvent. The dried lipid film was hydrated with 0.7 mL of
pH 7.4, 5 mM HEPES buffer solution and mildly vortexed for 20 seconds at room
temperature to obtain a suspension of bare cationic liposomes (bare LP). The suspension
was extruded 13 time through 100 nm polycarbonate membrane (Nucleopore, Pleasanton,
CA) by a Mini-Extruder (Avanti Polar Lipids, Alabaster, AL) at room temperature. Size
and ζ-potential of bare LP were measured by the Zetasizer. HEPES buffer (0.2 mL, 5
mM at pH 7.4) was added to dilute the resultant suspension of bare LP to 6.85 mM.
Preparation of bare cationic liposomes with MgP nanoparticles (bare LP/MgP).
Based on the phosphorus assay, 138.46 µL of MgP nanoparticles, which carry the
phosphoric concentration of 10.61 mM, was mixed with 0.3 mL of cationic, followed by
incubation for 1 hour at room temperature. Size and ζ-potential of bare cationic
liposomes with MgP nanoparticles (bare LP/MgP) were measured by the Zetasizer, for
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which 61.54 µL of pH 7.4, 5 mM HEPES buffer was added to obtain the final
formulation.
The preparation of stock solution of MitoRed for mitochondrial staining. To
prepare a 200 µM stock solution, 50 µg vial of MitoRed powder was dissolved in 460 µL
anhydrous DMSO.
The preparation of Hoechst 33342 working solution for nuclear staining. A
dilution of Hoechst 33342 was prepared in PBS for a final concentration of 1 mg/mL.
The resultant solution was diluted to 1 μg/mL in PBS for nuclear staining.
The preparation of cell culture and staining. The A549 cells were grown in
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12, 1:1 (DMEM/F-12, 1:1)
medium, supplemented with 10% fetal bovine serum (FBS), 1% antibiotics (penicillin
5000 U/mL, and streptomycin 5000 μg/mL) and 1% L-glutamine. A549 cells were
seeded in two 6-well plates (Ultra CruzTM, Santa Cruz Biotechnology) at a density of 2 x
105 cells/well and incubated under the condition of 5% CO2 at 37 ℃ overnight (12 hours)
to obtain 50% - 80% confluence.
The wells with or without cells were treated with 2 mL of different formulations
pre-diluted with culture medium to obtain 14.69 µM Alexa Fluor® 488-labeled CytC,
0.685 mM lipids, or 0.294 mM MgP in formulations. After incubation at 37 ℃ for three
hours, cells were washed once with PBS with 1 M NaCl solution for several seconds.
For the staining of mitochondria, MitoRed was diluted to 200 nM in pre-warmed
culture medium. PBS in cell wells was removed and 1 mL of the diluted MitoRed
solution was added into each well. Cells were incubated for 30 minutes at 37 ℃. The
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MitoRed solution was removed and cells were washed with culture medium once and
PBS once, each time for 3 minutes with the benchtop orbital shaker.
For fixation, cells were first washed with PBS. PBS was then removed followed
by addition of pre-warmed 4% paraformaldehyde (PFA) solution in PBS. Cells were
incubated for 17 minutes, and then washed with PBS twice for 3 minutes each time with
a benchtop orbital shaker.
For the staining of nuclei, cells were washed with PBS. After removing PBS, 1
mL of 1 μg/mL Hoechst 33342 solution was added to completely cover the cells in each
well. Aluminum foil was placed over the sample to protect it from light. Cells were
incubated at room temperature for 5 minutes and washed twice with PBS for 3 minutes
each time with the benchtop orbital shaker.
Fluorescence imaging assay. Fluorescent images were acquired with a
fluorescence microscope BZ-X710 (KEYENCE, Japan). Exact same parameters
(excitation light: 40%; objective lens: 4x; exposure time for BZ-X filter DAPI: 1/1.2
seconds; exposure time for BZ-X filter GFP: 3 seconds; exposure time for BZ-X filter
TxRed: 3s) were set for imaging all 6 different treatments (Alexa 488-labeled CytC,
Alexa 488-labeled CytC/MgP, bare LP/MgP, bare LP, Alexa 488-labeled CytC+MgP,
and no treatment) and their control groups with no cells.
Images under different filters were taken from each well and digitally
superimposed. The green fluorescence of the image _CH1 was from Alexa 488 labeledCytC in A549 cells, the red fluorescence of the image _CH2 was from mitochondria in
A549 cells, and the blue fluorescence of the image _CH3 was from nuclei in A549 cells.
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Each fluorescence intensity was measured using ImageJ from National Institutes of
Health (NIH) under the same thresholds.
4.3.2

Cell Viability Assay
A549 cells were grown in RPMI-1640 medium supplemented with 10% fetal

bovine serum (FBS), 1% antibiotics (penicillin 5000 U/mL, and streptomycin 5000
μg/mL) and 1% L-glutamine.
A549 cells were seeded in 96-well plates (Ultra CruzTM, Santa Cruz
Biotechnology) at a density of 5000 cells/well and incubated under 5% CO2 at 37 ℃
overnight (12 hours) to obtain around 50% to 80% confluence. Cells were treated with
100 µL of 6 different formulations (Free CytC, CytC LP/MgP, bare LP, bare LP/MgP,
MgP, and CytC+MgP). The formulations are prepared in the same way as those for the
aforementioned fluorescence imaging assay, each applied at 8 different concentrations by
pre-dilution with complete culture medium to carry 50, 10, 5, 1, 0.5, 0.1, 0.05 and 0.01
µM CytC, 428.47, 85.69, 17.14, 8.57, 4.28, 0.86, 0.43 and 0.09 µM total lipids, or 180,
36.7, 18.4, 3.67, 1.84, 0.367, 0.184, 0.0367 µM phosphate from MgP. After 48-hour
incubation at 37 ℃, cells were washed twice with PBS, each time for 3 minutes with the
benchtop orbital shaker.
Cell viability was measured by the MTS assay. 20 µL of CellTiter 96® AQueous
One Solution Reagent was added into each well of the 96-well plate containing 100 µL
culture medium without phenol red. After 4 hours of incubation at 37 ℃, the absorbance
of all the contents at 490 nm was measured by Biotek Synergy HT Multimode microplate
reader (BioTek Instruments, Winooski, VT). The absorbance of cells without any
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treatment was taken as 100% viability, and the absorbance of wells containing medium
but without cells was taken as background.
Cell viability was calculated by the following formula:
Cell Viability [%] =

OD490 sample−OD490 background
OD490 control−OD490 background

× 100%, where OD490 sample is the

UV absorbance of cells treated with a formulation at an aforementioned concentration,
OD490 control is the UV absorbance of cells treated with no formulation but growth
media as a control for 100% viability, and OD490 background is the UV absorbance of
wells with media but no cells.
Dose-response curves for cell viability of A549 cells treated with different
formulations were depicted, and the IC50 was calculated using GraphPad Prism (Version
6.01).
4.4

Results

4.4.1

Fluorescence Imaging of A549 Cells after Exposure to Formulations for 3 h
The A549 cells in 6-well plates were treated with formulations at 14.69 μM CytC,

0.685 mM total lipids, and 0.294 mM phosphate from MgP for 3 hours and the results of
the following florescent imaging are presented in Fig. 4 and Table 4.1.
Cells treated with free Alexa 488-labeled CytC did not display significant green
fluorescence (Fig. 4.1. (A) and Table 4.1.), indicating that Alexa 488-labeled CytC could
not efficiently penetrate through cell membrane into the A549 cells. Furthermore, CytC
LP/MgP caused much more cargo protein CytC attached to A549 cells than any other
formulations and the no-treatment group as indicated by the strongest green fluorescence
of the corresponding cells (Fig. 4.1. (B) and Table 4.1.).
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CytC LP/MgP and bare LP displayed less mitochondrial staining than other
formulations and the no-treatment group, (Fig. 4.2. (B), (C), (D) and Table 4.1.). In
addition, CytC LP/MgP and bare LP displayed more nuclear staining than other
formulations and the no-treatment group, (Fig. 4.3. (B), (C), (D) and Table 4.1.).

A

B

C

D
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Fig. 4.1. The attachment of Alexa 488-labeled cytochrome c to A549 cells after 3 h
incubation with (A)Alexa 488-labeled CytC, (B)Alexa 488-labeled CytC LP/MgP,
(C)bare LP/MgP, (D)bare LP, (E)Alexa 488-labeled CytC+MgP, and (F)no-treatment
group measured as shown by fluorescence microscopy.
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Fig. 4.2. The uptake and intramitochondrial accumulation of MitoRed in A549 cells after
3 h incubation with (A)Alexa 488-labeled CytC, (B)Alexa 488-labeled CytC LP/MgP,
(C)bare LP/MgP, (D)bare LP, (E)Alexa 488-labeled CytC+MgP, and (F)no-treatment
group measured as shown by fluorescence microscopy.
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Fig. 4.3. The uptake and intranuclear accumulation of Hoechst 33342 in A549 cells after
3 h incubation with (A)Alexa 488-labeled CytC, (B)Alexa 488-labeled CytC LP/MgP,
(C)bare LP/MgP, (D)bare LP, (E)Alexa 488-labeled CytC+MgP, and (F)no-treatment
group measured as shown by fluorescence microscopy.
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Table 4.1. Semi-quantitation of fluorescence intensity for staining of CytC, nuclei and
mitochondria in A549 cells.
CytC

Nuclei

Mitochondria

CytC

1±1

2511±34

25847±178

CytC LP/MgP

3616±42**

14305±114△△

376±18##

CytC+MgP

2±1

1564±23

43399±238

Bare LP

1±1

5959±53△△

5092±49##

Bare LP/MgP

1±1

6188±41△△

1440±27##

No treatment

1±1

2868±36

41564±203

Each value represents the mean±S.D. of at least three measurements. Significant
difference **P<0.01 vs. CytC of no treatment, △△P<0.01 vs. nuclei of no treatment, and
##
P<0.01 vs. mitochondria of no treatment (Student’s t-test).

4.4.2

MTS Assay on A549 Cell Viability after Exposure to Formulations for 48 h
The highest concentration of total lipids in wells of 96-well plates is 0.428 mM,

and of phosphate from MgP is 0.184 mM. Free CytC showed relatively high cytotoxicity
at low concentrations. At the same time, high cytotoxicity was observed in a
concentration-dependent manner for bare LP with or without MgP. However, lower
cytotoxicity was found from CytC LP/MgP than from bare LP with or without MgP.
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Fig. 4.4. MTS assay on cell viability after exposing A549 Cells to free CytC (blue), CytC
LP/MgP (purple), bare LP/MgP (red), bare LP (green), CytC+MgP (dark green), and
MgP (orange) for 48 h.

Table 4.2. IC50 normalized by the concentration of CytC.

IC50 of
CytC
(µM)

Free
CytC

Bare
LP/MgP

Bare LP

CytC
LP/MgP

CytC LP

MgP

CytC+M
gP

~ 0.231

1.23

1.179

10.59

14.98

~ 9.21

~ 243.1

4.5

Discussion

4.5.1

Fluorescence Imaging
Sephadex® G-50 Fine gel filtration resin (GE Healthcare Life Sciences,

Pittsburgh, PA) for the separation of molecules from 1,000 to 30,000 Dalton was used
first to separate the conjugate from unreacted labeling reagent. However, the CytC
(labeled or unlabeled) was poorly resolved from unreacted Alexa 488 dye on a 25 cm
column, as indicated by Fig. 4.5, suggesting that CytC and unreacted Alexa 488 dye were
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collected as a mixture. The poor resolution may be partly due to the small molecular
weight of CytC (12 kDa).

Fig. 4.5. Column chromatography by Sephadex® G-50 Fine.

Sephadex® G-25 Medium gel filtration resin (GE Healthcare Life Sciences,
Pittsburgh, PA) with a separation range of 1000 to 5000 Dalton was then attempted to
improve the resolution. However, the CytC (labeled or unlabeled) was poorly resolved
from unreacted Alexa 488 dye by a 25-cm column, as indicated by lack of two separate
peaks of Alexa 488-labeled CytC and unreacted Alexa 488 dye by UV-Visible
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Spectrometry readout at 488 nm (Fig. 4.6., the signal at 550 nm is from CytC), which
meant CytC and unreacted Alexa 488 dye were collected simultaneous as a mixture.

Fig. 4.6. UV-Visible Spectrometry readout for the separation of (yellow) CytC at 550 nm
from (blue) Alexa 488 dye at 488 nm by Sephadex® G-25 Medium.

Eventually, Amicon® Ultra 15 mL centrifugal filter (EMD Millipore, Billerica,
MA) with 3 kDa molecular weight cutoff allowed the separation of cytochrome c from
the unreacted dye molecules whose molecular weight is smaller than 3 kDa. The proteindye mixture was centrifuged twice on Centrifuge 5810 R (Eppendorf, Germany) at 4000
x g at 25 ℃ (1 h each time) to yield the labeled cytochrome c at a recovery rate of ~60%.
Jones et al. reported that CytC contains cell penetrating peptide (CPP) epitopes in
the N- and C-terminal helices. Such CPPs can mediate the cellular uptake of free CytC
protein [26]. The reason why Alexa 488-labeled CytC could not distribute into cells
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might be that after NHS esters (or succinimidyl esters) of Alexa Fluor® 488 reacted with
non-protonated aliphatic amine groups of proteins to form stable carboxamide bonds, the
conjugated Alexa 488 moiety hindered the cell penetrating peptide (CPP) epitopes in the
N-terminal helices of CytC.
All formulations containing the cationic lipid DOTAP reduced the uptake and
intramitochondrial accumulation of MitoRed, which is probably due to the change of
mitochondria’s inner transmembrane potential (m) by DOTAP based on prior reports
of mitochondrial staining. Petit et al. reported that the uptake of the fluorochrome
Rhodamine 123 into mitochondria was reduced in pre-apoptotic cells [27]. The authors
found that the fluorophore accumulated into the mitochondrial membrane matrix space in
inverse proportion to m in a Nernst fashion, and thus proposed that the reduced dye
uptake was due to the m dissipation. Moreover, Perry et al. reported that
depolarization of m caused lower concentration of Rhodamine 123 in mitochondria,
and vice versa. [28]. MitoRed is a cell membrane permeable Rhodamine-based dye that
localizes in mitochondria and emits red fluorescence. The interaction of MitoRed with
mitochondria depends on the membrane potential of mitochondria. Thus, the reduced
mitochondrial staining of MitoRed strongly suggests that DOTAP in the proposed
formulation of our project causes pre-apoptosis of A549 by dissipating the
mitochondria’s inner transmembrane potential.
All formulations containing cationic lipid DOTAP increased the uptake and
intranuclear accumulation of Hoechst 33342. Faleiro et al. found that caspase-9, which is
activated earlier than caspase-3, directly or indirectly increases permeability of nuclear
pores. This increment allows caspase-3 and other molecules that could not pass through
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nuclear pores in living cells to enter or leave the nucleus during apoptosis by diffusion
[29]. Therefore, the increased nuclear staining by Hoechst 33342 in cells treated with
formulations with DOTAP again attests DOTAP’s apoptotic effect on the A549 cells.
It is not totally clear whether Alexa 488-labeled CytC is outside or inside of A549
cells. This can be resolved as future work by using confocal microscopy with higher
magnification. In addition, membrane impermeable fluorescent quenchers can be applied
to the outside of such cells to test whether the fluorescence of Alexa 488-labeled CytC
can be changed: a reduction of the fluorescence would indicate the formulation is still on
the cell surface and vice versa.
4.5.2

Cell Viability Assay
Our data showed that free CytC caused the strong cytotoxicity, which is intriguing

in the context of prior reports on CytC’s effects on cell viability. Among earlier
investigations, Piel et al. found that after intravenous injection in a septic mice model,
bovine heart CytC was taken up by cardiomyocytes and significantly improved
cardiomyocytes’ mitochondrial function. Further, the survival rate of the cardiomyocytes
increased from 15% to about 50% in the septic mice that received CytC injections [20],
[21]. These findings may seem puzzling because CytC not only has to be taken up by
cells, but also must translocate across the cell membrane to accumulate in mitochondria.
This is now better explained by Jones et al, who showed that CytC contains cell
penetrating peptide (CPP) epitopes in the N- and C-terminal helices [26]. Such CPPs can
mediate the cellular uptake of various proteins. Therefore, cytotoxicity of free Alexa
488-labeled CytC needs to be evaluated in the future to validate whether the conjugated
Alexa 488 moiety hindered CPPs in the N-terminal helices of CytC.
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Nevertheless, another question needs to be addressed: why does the treatment
with exogenous CytC, which will be taken up into the cytosol first, not amplify the
apoptotic cascade but instead lead to increased survival of the cardiomyocytes in septic
mice? This phenomenon conforms with our data that lower cytotoxicity was found from
CytC LP/MgP than from bare LP with or without MgP. There were three likely
interpretations. First, cationic lipid DOTAP changes mitochondrial membrane potential,
generates reactive oxygen species (ROS), dissociates CytC from the inner mitochondrial
membrane, forms the mitochondrial outer membrane permeabilization pore (MOMPP),
releases CytC from mitochondria, and induces apoptosis in different cell lines, all of
which confirmed by Aramaki et al. [15]. The release of endogenous CytC, which is an
essential component of the electron transport chain (ETC leads to mitochondrial
dysfunction. It has long been known that isolated mitochondria can reversibly release
and take up CytC, while the latter restores mitochondrial function, as demonstrated by
Jacobs and Sanadi [19], Doran and Halestrap [32]. Thus, exogenous CytC delivered by
CytC LP/MgP in the cytosol could enter mitochondria to restore ETC activity of
mitochondria and thus increase the cell viability. This explanation was supported by the
aforementioned studies of an animal model for sepsis [20], [21].
As the second interpretation, Zhivotovsky et al. and Li et al. reported that CytCinduced apoptosis is dependent on the concentration of the cytosolic CytC [30], [31].
Clayton et al. explained that endogenous CytC release occurs proportionally to the extent
of cellular ‘stress’, and each cell, even from the same cell line, responds to a certain
threshold of the released CytC to progress into apoptosis [23]. Zhivotovsky et al. found
that microinjected 10 µM or 20 µM CytC could induce apoptosis in various cell types,
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and this effect was dependent on the cytosolic CytC concentration. Nevertheless, the
apoptotic effect of 20 µM exogenous CytC was totally reversed when rat kidney (NRK)
epithelial cells were transfected to express Bax/Bak, which are members of Bcl-2 family
proteins known to induce formation of MOMPP (Fig. 4.7.) [30]. In this case, the
exogenous CytC entered mitochondria through MOMPP by active transport [32], leading
to a great decrement of cytosolic CytC concentration and protection of MOMPPexpressing cells from apoptosis. Cationic lipid DOTAP also leads to formation of the
mitochondrial outer membrane permeabilization pore (MOMPP) [15]. Therefore, after
the cells were exposed to CytC LP/MgP, DOTAP would induce MOMPP formation in
the affected pre-apoptotic cells, followed by a translocation of the exogenous cargo
protein CytC from the cytosol into the mitochondria. This would then protect the
DOTAP-injured cells from entering apoptosis, resulting in higher cell viability.
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Fig. 4.7. Effect of CytC microinjection in normal rat kidney (NRK) epithelial cells. Wildtype cells were injected with 20 µM (dark red) or 10 µM (green) CytC. Cells expressing
MOMPP were injected with 20 µM CytC (orange) [30].

As the third possible interpretation, free CytC also functions as a universal radical
scavenger within the mitochondrial inner-membrane space. Because CytC constantly
undergoes oxidation/reduction cycles in a respiring cell, it contributes to detoxification
reactions against superoxide and hydrogen peroxide [22]. It is known that cationic lipid
DOTAP enhances generation of reactive oxygen species (ROS), which eventually
induces apoptosis [15]. Exogenous CytC delivered by CytC LP/MgP in the cytosol may
act as a ROS scavenger like catalase, which removes DOTAP-generated ROS, and rescue
cells from DOTAP-induced apoptosis.
Although the mechanism is still unclear, CytC decreases cytotoxicity of cationic
lipids, which will facilitate the pharmaceutical applications of the latter in drug delivery
systems.
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4.6

Conclusion
CytC LP/MgP successfully led to the attachment of CytC to A549 cells.

Intracellular delivery of CytC alleviated the cytotoxicity of cationic lipids in A549 cells,
which could facilitate the clinical use of cationic lipids in drug delivery systems.
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